NCT02819843

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this phase II clinical study is to test the good and bad effects of T-VEC (talimogene laherparepvec) with or without hypofractionated radiotherapy on people with melanoma, Merkel cell carcinoma, or other solid tumors with skin metastasis.

Conditions

• Melanoma
• Merkel Cell Carcinoma
• Other Solid Tumors

Interventions

Type	Name	Description
DRUG	TALIMOGENE LAHERPAREPVEC (TVEC)
RADIATION	Hypofractionated Radiotherapy

Timeline

• Start date: 2016-06-21
• Primary completion: 2024-02-22
• Completion: 2024-02-22
• First posted: 2016-06-30
• Last updated: 2025-01-29
• Results posted: 2025-01-29

Locations

3 sites across 1 country: United States